AstraZeneca Group News

Data Presented at the European Atherosclerosis Society Congress Reinforces the Differentiating Benefits of CRESTOR[TM] in Comparison to Atorvastatin and Simvastatin Data presented today from the VOYAGER study demonstrate the benefits of aggressive statin therapy with CRESTOR in comparison to atorvastatin and simvastatin in high risk patients.

AstraZeneca PLC announced that on 23 May 2012, it purchased for cancellation 600,000 ordinary shares of AstraZeneca PLC at a price of 2610 pence per share.

Drug Giants Such as AstraZeneca PLC , GlaxoSmithKline , Sanofi Join Forces With Academia on $285 Million Antibiotic Pact GlaxoSmithKline and AstraZeneca welcomed the launch of a pioneering approach to antibiotic research in Europe that will see pharmaceutical and biotechnology companies working alongside public partners to tackle the rising threat ... (more)

Among the companies whose shares are moving in pre-market trading Tuesday are STMicroelectronics, Ceragon Networks, Trina Solar, Vodafone Group, Mellanox Technologies, Nokia Corp, Cellcom STMicroelectronics NV stock surged 6.07 percent to $5.07 in pre-market session.

AstraZeneca PLC announced that on 18 May 2012, it purchased for cancellation 600,000 ordinary shares of AstraZeneca PLC at a price of 2624 pence per share.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Having suffered a series of late-stage setbacks, AstraZeneca expects to ink several agreements very soon that will boost its pipeline.

Shareholder revolts have claimed the jobs of a handful of Britain's most high profile bosses in the last couple of months, among them David Brennan, the chief executive of drugs giant AstraZeneca .A After six years in the role, Brennan is leaving under a cloud of concern about the drug giant's ability to replenish its product pipeline at a quicker ... (more)

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Amylin Pharmaceuticals, Inc.

Executive director and CFO Simon Lowth will act as interim CEO following Brennan's departure, until a new CEO can be found, while VP group finance Julie Brown will become interim CFO.

Amylin has apparently attracted interest from potential suitors including Pfizer , AstraZeneca , Bristol-Myers and Sanofi , all of which have signed confidentiality agreements on the drugmaker's sale process.

AstraZeneca PLC announced that on 14 May 2012, it purchased for cancellation 525,500 ordinary shares of AstraZeneca PLC at a price of 2665 pence per share.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia AstraZeneca PLC Release: SYMBICORTA Long-Term Study Shows Similar Safety Profile When Compared to Budesonide Monotherapy in African-American Patients with Asthma WILMINGTON, ... (more)

AstraZeneca has had a lackluster stock price performance in recent years. Despite the lackluster stock price performance, AstraZeneca sports a high dividend yield of 6.37%, and has increased its dividend rate every year for the last ten years.

AstraZeneca opened at 43.44 on Thursday. AstraZeneca has a 1-year low of $40.89 and a 1-year high of $52.54. The company has a market cap of $55.343 billion and a price-to-earnings ratio of 6.66. AstraZeneca last released its earnings data on Thursday, April 26th.

Bonus payouts are expected to fall by 48 percent to 2.3bn, year-on-year, according to the latest data from The Centre for Economics and Business Research .

EVERY weekday morning from The Week online - a daily wrap-up of the best comment and opinion articles from the morning papers and the top political bloggers.

Further to the announcement of its irrevocable, non-discretionary share repurchase programme for the period 5 March 2012 to 11 May 2012, AstraZeneca PLC announced that under the terms of that programme it purchased for cancellation 313,798 ordinary shares of AstraZeneca PLC at a price of 2709 pence per share on 8 May 2012.

The departure of Andrew Moss from his position as chief executive of Aviva, our largest insurance group, comes only days after the forced exit of two other bosses who have disappointed shareholders - Sly Bailey of newspaper publisher Trinity Mirror and David Brennan of pharmaceuticals company AstraZeneca.

Shareholders have claimed another high-profile scalp after Britain's biggest insurer announced the abrupt exit of its chief executive.

Andrew Moss has bowed to investor pressure and stepped down from the helm at Aviva , becoming the latest casualty of shareholder revolt over corporate pay levels.